Ondine Biomedical Inc: 2019 Visionary Finalist - PwC Canada’s Vision to Reality (#V2R) Awards

Ondine nominated for its breakthrough and life-saving PDT technology - photodisinfection

Congratulations to Carolyn Cross, Chairman and CEO, Ondine Biomedical and IPA board member, for being recognized as one of PwC Canada’s Vision to Reality (#V2R) Awards finalists in the visionary category.

Ondine nominated for its breakthrough and life-saving PDT technology, photodisinfection, which directly targets the global threat of multi-drug resistance. In minutes Ondine's patented, light-activated antimicrobial system kills bacteria, viruses, and fungi—including superbugs—of all kinds without the use of antibiotics.

Its flagship universal nasal photodisinfection has been deployed at leading Canadian hospitals for several years, preventing hundreds of surgical site infections which would otherwise have resulted in patient morbidity, mortality and millions of dollars of unnecessary annual cost.

A recent abstract published at the 19th Annual Scientific Conference of the Canadian Spine Society found that the impact on post spine surgery infections at Vancouver General Hospital over a period of eight years was highly significant. The results showed a 78% reduction in surgical site infection rate and found one infection was prevented for every 18 patients treated. $4.24 million was saved annually, and no adverse events were reported. As a result, nasal Photodisinfection is being recommended for routine use in all spine surgeries in Canada. 

Ondine Biomedical Inc. received fast track designation from the US FDA for its Nasal Photodisinfection System. 
 

Find out more at: www.ondinebio.com